Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function.

Abstract

A teenager who acquired 2009 H1N1 influenza A lower respiratory tract infection during total bone marrow and lymphoid aplasia, in the setting of human leukocyte antigen-haploidentical hematopoietic stem cell transplantation, was successfully treated with intravenous zanamivir. This case demonstrates efficient control of pandemic influenza infection by intravenous zanamivir in the absence of any functional immune system, thus suggesting profound antiviral activity.

• Authors: S Ghosh, O Adams, F R Schuster, A Borkhardt, R Meisel
• Journal: Transplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 14 Issue 6 Pg. 657-9 (Dec 2012) ISSN: 1399-3062 [Electronic] Denmark
• PMID: 23013415 (Publication Type: Journal Article)
• Copyright: © 2012 John Wiley & Sons A/S.

Chemical References

• Antineoplastic Agents
• Antiviral Agents
• Zanamivir

Topics

• Adolescent
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antiviral Agents (therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Immunocompromised Host
• Influenza A Virus, H1N1 Subtype
• Influenza, Human (drug therapy, virology)
• Pandemics
• Zanamivir (therapeutic use)